Inotersen (Tegsedi®). HTA ID: 19034
Inotersen (Tegsedi®) is indicated for the treatment of Stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin (TTR) amyloidosis (hATTR).
NCPE Assessment Process | Complete |
Rapid review commissioned | 26/08/2019 |
Rapid review completed | 07/10/2019 |
Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inotersen compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 09/10/2019 |
Pre-submission consultation with Applicant | 08/12/2020 |
Full HTA submission received from Applicant | 23/07/2021 |
Preliminary review sent to Applicant | 05/10/2021 |
NCPE assessment re-commenced | 02/11/2021 |
Factual accuracy check sent to Applicant | 22/12/2021 |
NCPE assessment re-commenced | 10/01/2022 |
NCPE assessment completed | 11/02/2022 |
NCPE assessment outcome | The NCPE recommends that inotersen be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.